Cybin Company Presentation

Unmet Medical Need 30-50% of patients receiving treatment for various forms of depression or addiction do adequately respond to therapy Changing Social Acceptance Cannabis legalization at various levels indicates a willingness to re-examine societal beliefs related to formerly demonized drugs US$25B Market Opportunity Spending on Depression and Addiction treatments globally Growth to US$35B (2029) 3.5% CAGR through 2029 (1) Source: private report prepared by TMR, 2020 (www.tmrresearch.com ) (2) https://qz.com/1162154/30-years-after-prozac-arrived-we-still-buy-the-lie-that-chemical-imbalances-cause-depression/ (3) https://www.theguardian.com/society/2016/jan/27/prozac-next-psychiatric-wonder-drug-research-medicine-mental-illness (4) Forward-looking statements are subject to various risks and assumptions. See “Cautionary Statement Regarding Forward- Looking Information” on page 2 of this presentation. Pharmaceutical Market Size Highlights (1) 10 P r i v a t e & C o n f i d e n t i a l Big pharma stopped searching for the next Prozac “The theory fits in with psychiatry’s attempt over the past half century to portray depression as a disease of the brain instead of an illness of the mind” (2) Taking a drug to tweak the biological chemical imbalances in the brain makes intuitive sense, but depression isn’t caused by a chemical imbalance “As patents started to expire, they realised it was pretty hard to replace those with anything that was truly new” (3) Cybin is committed to discovering the path that psychedelics may take to retrain thought patterns and enhance neural networks in the brain (4)

RkJQdWJsaXNoZXIy NDMyMDk=